| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | IceCure Medical: IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales | 102 | PR Newswire |
Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution for the local... ► Artikel lesen | |
| ICECURE MEDICAL Aktie jetzt für 0€ handeln | |||||
| 08.01. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 17.12.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.12.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.12.25 | IceCure Medical: IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes | 125 | PR Newswire | Cryogenic flow control enhances the efficacy and precision of cryoablation procedures
Robust IP portfolio becomes increasingly strategic as global interest in IceCure's... ► Artikel lesen | |
| 03.12.25 | IceCure Medical beruft außerordentliche Hauptversammlung für Januar 2026 ein | 2 | Investing.com Deutsch | ||
| 03.12.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.11.25 | IceCure Medical reports nine months ended results | 3 | Seeking Alpha | ||
| 19.11.25 | IceCure Medical: IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 | 250 | PR Newswire | Momentum building in the U.S. and rising interest globally following landmark FDA marketing authorization for local cryoablation treatment of low-risk breast... ► Artikel lesen | |
| 18.11.25 | What's Next: Icecure Medical's Earnings Preview | 1 | Benzinga.com | ||
| 18.11.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.11.25 | IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification | 546 | PR Newswire | CAESAREA, Israel, Nov. 14, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that... ► Artikel lesen | |
| 10.11.25 | IceCure Medical: IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction | 118 | PR Newswire | Mr. Levav's appointment ensures seamless and focused organizational structure as Company expands commercial activities in the U.S. following FDA marketing clearance for ProSense® CAESAREA... ► Artikel lesen | |
| 10.11.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.11.25 | IceCure Medical: Positive Studienergebnisse zur Kryoablation lassen Aktie steigen | 3 | Investing.com Deutsch | ||
| 03.11.25 | IceCure Medical: IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival | 168 | PR Newswire | 5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 74%, compared to published studies reporting 5-year OS of 41% - 52% with SBRT... ► Artikel lesen | |
| 03.11.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 17.10.25 | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 07.10.25 | IceCure Medical stock price target raised to $2.50 from $2.00 at H.C. Wainwright | 3 | Investing.com | ||
| 06.10.25 | ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment | 3 | Zacks |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VENUS CONCEPT | 7,940 | +455,24 % | Venus Concept Stock Explodes Over 500% After Major Investor Takes Control | ||
| ALIGNMENT HEALTHCARE | 22,500 | 0,00 % | Alignment Healthcare Reports 31% Year-Over-Year Membership Growth to 275,300 as of Jan. 1, 2026 | Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million in 2026 will be within its full-year... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,650 | -4,59 % | BERNSTEIN RESEARCH stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Siemens Healthineers auf "Outperform" mit einem Kursziel von 52,90 Euro belassen. 2025 sei ein schlechtes Jahr... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,100 | +0,46 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung gemäß Artikel 5 Abs. 1 lit. a) der Verordnung (EU) Nr. 596/2014 und Artikel 2 Abs. 1 der Delegierten... ► Artikel lesen | |
| GENEDX | 108,08 | -1,10 % | Sema4.ai: Interview With Co-Founder & CEO Rob Bearden About The Enterprise AI Agent Platform | ||
| BRIGHTSPRING HEALTH SERVICES | 39,200 | -1,01 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 30,380 | -0,39 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| FRESENIUS | 49,370 | -0,56 % | Aktien Frankfurt: Dax setzt Rekordrally mit kleinem Schrittchen fort | FRANKFURT (dpa-AFX) - Der Dax hat am Montag nach einem zunächst stabilen Börsenauftakt an seinen zum Jahresbeginn wieder aufgenommenen Rekordlauf angeknüpft. Um die Mittagszeit legte der deutsche Leitindex... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 37,520 | -5,40 % | Bechtle, Carl Zeiss Meditec, CTS Eventim, MTU Aero Engines, Suss MicroTec, TeamViewer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| PROGYNY | 24,520 | +0,86 % | Progyny, Inc. - 8-K, Current Report | ||
| HEARTFLOW | 37,160 | +2,88 % | Heartflow, Inc. - 8-K, Current Report | ||
| BETA BIONICS | 18,500 | +3,99 % | Beta Bionics, Inc.: Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 | ||
| DRAEGERWERK | 92,00 | +14,57 % | Draegerwerk AG & Co. KGaA: Fokus auf die Bewertung: Kursziel erreicht. Von KAUFEN auf HALTEN. | Die Aktien von Drägerwerk (Dräger) sind seit Beginn des Jahres 2026 um nahezu 10% gestiegen, was den Kurs der Aktie nahe an unser Kursziel von 76,00 EUR bringt und eine Herabstufung von "Kaufen" auf... ► Artikel lesen | |
| BILLIONTOONE | 88,73 | -6,32 % | BillionToOne, Inc.: BillionToOne Provides Guidance for 2026 | MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| GERRESHEIMER | 25,720 | -1,83 % | Buy or Goodbye?: Bayer, BMW, Gerresheimer und Hellofresh - Die Analystenstimmen des Tages | © Foto: Bernd von Jutrczenka - dpaBayer, BMW, Gerresheimer und Hellofresh: Die wichtigsten Analysten-Updates im Überblick.Jefferies stuft Gerresheimer auf "Buy" Das Analysehaus Jefferies hat die Einstufung... ► Artikel lesen |